Located in Hsinchu Industrial Park, Intech Biopharm’s new pharmaceutical factory, which specializes in the manufacturing of drugs for obstructive airway diseases, was inaugurated on September 20th. Vice President Chen Chien-jen was present at the ceremony, commending Intech Biopharm for its constant innovation in R&D and relentless effort into expanding overseas markets and enhancing the reputation of Taiwan-based companies. He was also optimistic about the biotech industry, which in his opinion will become the new engine to drive Taiwan’s economic development and improve people’s welfare.
Hsinchu County Magistrate Chiu Ching-Chun said that Hsinchu Industrial Park has the highest density of pharmaceutical companies in Taiwan, enjoying advantages of its plentiful professionals and highly accessible location. Besides, Intech Biopharm’s parent company, Synmosa Group, also has other factories in Hsinchu Industrial Park, with roughly 300 workers in total. Magistrate Chiu showed respect for Chairman Lin Zhi-hui’s dedication to the development of technology platforms and pharmaceutical factories. He also expressed his gratitude to Chairman Lin for investing locally while making money worldwide.
Chairman Lin stated that Intech Biopharm is a listed pharmaceutical company at emerging stock market. Keeping its spirit—local operation, global vision—in mind, Intech Biopharm focuses mainly on the R&D of inhalants with a high barrier to entry. It has successfully rivaled its major competitors, such as GSK, AstraZeneca, Boehringer Ingelheim and TEVA, in terms of pharmaceutical technologies. With cutting-edge technologies behind, Intech Biopharm has become one of the rare inhalant suppliers in the world to share a market of up to USD30 billion.
After the new facility starts operating, the first batch of experimental drugs SYN011 will be manufactured. Intech Biopharm will also apply for drug evaluation in the US and apply to Taiwan Food and Drug Administration (TFDA) for PIC/S GMP certification. Base on international norms and standards for pharmaceuticals, Intech Biopharm will be dedicated to the establishment of automated equipment and the drug traceability system in the future. With high standard facilities and high value-added products, Intech Biopharm is looking forward to becoming a well-known pharmaceutical brand that not only creates profits but also raises the value and reputation of Taiwan’s biotech industry.